Story
Sanofi Shares Fall After Scrapping Key Immunology Drug Amlitelimab
Summary
Sanofi has ceased all clinical development of amlitelimab for atopic dermatitis, a key pipeline asset, citing an unfavorable risk-benefit profile. The decision has intensified investor concerns about the company's future growth beyond its blockbuster drug Dupixent.
Shares of Sanofi fell on Friday after the French pharmaceutical company announced it was halting all clinical development of amlitelimab for moderate-to-severe atopic dermatitis. The decision sent the company's stock down 1.7% to trade at €75.04 in morning trading.
Development Halted
Sanofi stated that after reviewing the complete body of evidence, the drug's combined efficacy and safety profile did not justify pursuing global regulatory submissions for the atopic dermatitis indication. The company concluded that the "totality of efficacy and safety evidence generated to date does not support further development."
Despite the setback, Sanofi confirmed that it is not revising its full-year 2026 financial guidance. The market reaction, however, indicates that investors view the loss of the pipeline candidate as a significant strategic blow.
A Blow to the Pipeline
Amlitelimab was widely seen by analysts as a promising asset to eventually succeed Sanofi's immunology mega-blockbuster, Dupixent. The drug was a central part of Sanofi's $1.1 billion acquisition of Kymab in 2021.
AdAnalysts had previously trimmed peak sales estimates for the drug to approximately €1 billion following a Phase 3 trial in September 2025 that, while meeting its primary endpoints, fell short of market expectations. Today's announcement removes a key potential growth driver from Sanofi's near-term pipeline.
Investor Concerns Mount
The termination of the amlitelimab program reinforces investor concerns about Sanofi's heavy reliance on Dupixent and its ability to develop or acquire new assets before the blockbuster loses exclusivity. The company has faced several disappointing clinical readouts since 2025, increasing pressure on its R&D strategy.
Sanofi's stock decline was driven by company-specific news, standing in contrast to the broader French market. The stock is now trading closer to its 52-week low of €71.25 than its high of €91.15, reflecting persistent headwinds. The announcement sets a cautious tone ahead of the company's next earnings report, scheduled for the end of the month.
Read next
More on Stocks
River Cruise Industry Can Adapt to Climate Change Risks, Bernstein Says
Bernstein analysts report that while European river cruises face more frequent disruptions from low water levels due to climate change, the industry has sufficient adaptation strategies to ensure its long-term viability.
Aramco Reportedly Explores Standalone Gas Unit With Potential $100 Billion Valuation
Saudi Aramco is reportedly considering a major restructuring to create a standalone natural gas division, which could be valued at over $100 billion and potentially be listed or sold to new investors.
Apple Ordered to Pay Record $5.7 Billion in Haptic Patent Case, Plans to Appeal
A U.S. jury found Apple's Taptic Engine infringed on two patents held by Taction, ordering a landmark $5.7 billion payment. The tech giant has stated it will appeal the verdict.
Northern Star Rejects Takeover Overture From Gold Fields, Bloomberg Reports
South Africa's Gold Fields Ltd. recently approached Australia's Northern Star Resources about a potential acquisition, but the offer was rejected, according to a report. The move comes as Northern Star faces pressure from an activist investor and deals with operational challenges.